PFE heads into Q4 earnings with strong oncology and Vyndaqel demand, but IRA headwinds, COVID declines and falling estimates weigh on the outlook ...
Global pharmaceutical company Pfizer (NYSE:PFE) beat Wall Street’s revenue expectations in Q4 CY2025, but sales fell by 1.2% ...
Zacks Investment Research on MSN
Earnings preview: Pfizer (PFE) Q4 earnings expected to decline
Wall Street expects a year-over-year decline in earnings on lower revenues when Pfizer (PFE) reports results for the quarter ended December 2025. While this widely-known consensus outlook is important ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results